Journal
CHEST
Volume 127, Issue 4, Pages 1312-1326Publisher
ELSEVIER
DOI: 10.1378/chest.127.4.1312
Keywords
asthma; cytokines; eosinophils; inflammation; leukotrienes; leukotriene receptor antagonists; remodeling; rhinitis
Categories
Ask authors/readers for more resources
Systemically bioavailable leukotriene receptor antagonists (LTRAs) can reduce the essential components of allergic inflammation in allergic rhinitis (AR) and asthma by blocking cysteinyl leukotriene (CysLT) activity, resulting in a wide range of clinical effects. CysLTs, mediators, and modulators in the pathophysiology of asthma and AR are a key target for therapy because they modulate production of hemopoietic progenitor cells, survival and recruitment of eosinophils to inflamed tissue, activity of cytokines and chemokines, quantity of exhaled NO, smooth-muscle contraction, and proliferation of fibroblasts. The mechanism of action of LTRAs leads to their effects on systemic allergic inflammatory processes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available